Last reviewed · How we verify
PiB
PiB (Pittsburgh Compound B) is a positron emission tomography (PET) tracer that binds to amyloid-beta plaques in the brain to enable imaging and detection of amyloid pathology.
PiB (Pittsburgh Compound B) is a positron emission tomography (PET) tracer that binds to amyloid-beta plaques in the brain to enable imaging and detection of amyloid pathology. Used for PET imaging of amyloid-beta burden in patients with cognitive impairment or suspected Alzheimer's disease, Research and clinical assessment of amyloid pathology in neurodegenerative diseases.
At a glance
| Generic name | PiB |
|---|---|
| Sponsor | NYU Langone Health |
| Drug class | PET imaging tracer |
| Target | Amyloid-beta (Aβ) fibrils |
| Modality | Small molecule |
| Therapeutic area | Neurology / Alzheimer's Disease |
| Phase | FDA-approved |
Mechanism of action
PiB is a carbon-11 labeled imaging agent that crosses the blood-brain barrier and selectively binds to fibrillar amyloid-beta aggregates in Alzheimer's disease and related neurodegenerative conditions. The radioactive tracer allows visualization and quantification of amyloid burden via PET imaging, facilitating early detection and monitoring of amyloid pathology in the brain. This enables clinicians and researchers to assess amyloid load non-invasively in patients with cognitive impairment or at risk for Alzheimer's disease.
Approved indications
- PET imaging of amyloid-beta burden in patients with cognitive impairment or suspected Alzheimer's disease
- Research and clinical assessment of amyloid pathology in neurodegenerative diseases
Common side effects
- Radiation exposure (minimal from diagnostic dose)
Key clinical trials
- Brain Blood Flow and Sugar Transport in Alzheimer's Disease With and Without Diabetes - A Pilot Imaging Study
- Molecular and Structural Imaging in Alzheimer's Disease: A Longitudinal Study (NA)
- Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in Pregnancy in Women With Hepatitis C With and Without HIV (PHASE1, PHASE2)
- Study of Biodistribution, Metabolism, Excretion and Brain Uptake 18F-JSS20-183A (EARLY_PHASE1)
- Biodistribution of [11C]PIB in Patients With Risk Factors for Alzheimer's Disease
- UAB Alzheimer's Disease Center Core Cohort - Imaging Substudy (PHASE2)
- Rapid HCV Treatment Access for Persons Who Use Drugs (NA)
- Olvi-Vec Combined With Platinum Plus Etoposide Therapy in Patients With Late Phase SCLC (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |